FY25 saw strong revenue growth and commercial progress, with Tutivia test adoption accelerating and Medicare coverage secured. Cash runway extends to end-2026 after two equity raises, but further funding will be needed. Significant upside expected from new products and expanded market access.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.